Products
Pre-made Technetium (99Mtc) Nofetumomab Merpentan benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-1012
Anti-MS4A1/CD20 therapeutic antibody (Pre-made Technetium (99Mtc)
Nofetumomab Merpentan biosimilar, Radiolabelled antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Technetium (99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer,[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.[2] The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc).[3]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-1012-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-1012-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-1012-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-1012-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Technetium (99Mtc) Nofetumomab Merpentan Biosimilar, Radiolabelled Antibody: Anti-MS4A1/CD20 therapeutic antibody |
| INN Name | Technetium (99Mtc) Nofetumomab Merpentan |
| Target | MS4A1/CD20 |
| Format | Radiolabelled antibody |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | Fab - G2b - kappa |
| VD LC | Fab - G2b - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | NeoRx Corp. (Seattle WA USA) / Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) / DuPont Merck Pharmaceutical (Billerica MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
